Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.40 |
| ▸ | MEF2D | Q14814 | 7/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | RHOA | P61586 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22347911 | 0.91 | PKM (0.49) | PKML3MBTL1PRMT1HDAC4MEF2D | |
| SCHEMBL22350273 | 0.89 | NR1H4 (0.48) | PKMHDAC4MEF2DSIRT1MEN1 | |
| SCHEMBL22347817 | 0.87 | THRB (0.53) | PKML3MBTL1HDAC4MEF2DMEN1 | |
| SCHEMBL22350274 | 0.85 | CCNB2 (0.35) | MAOB | |
| SCHEMBL22347648 | 0.84 | NR1H4 (0.32) | HDAC4MEF2D | |
| SCHEMBL22350200 | 0.81 | NR1H4 (0.48) | PKMSIRT1MEN1KMT2AGLA | |
| SCHEMBL29901055 | 0.81 | NR1H4 (0.48) | PKMSIRT1MEN1KMT2AGLA | |
| SCHEMBL22348075 | 0.79 | PARP1 (0.40) | L3MBTL1MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL22350237 | 0.78 | NR1H4 (0.59) | HDAC4MEF2DSIRT1MEN1KMT2A | |
| SCHEMBL29900950 | 0.78 | NR1H4 (0.59) | HDAC4MEF2DSIRT1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030835-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220213026-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| EP-3924333-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020168149-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213026-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | PKM 3271/4885L3MBTL1 1645/4885PRMT1 1544/4885 |
| US-12030835-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | PKM 3271/4885L3MBTL1 1645/4885PRMT1 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.